Triggering Receptor Expressed on Myeloid cells-1: a new player in platelet aggregation

Summary

Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor initially known to be expressed on neutrophils and monocytes/macrophages. TREM-1 acts as an amplifier of the inflammatory response during both infectious and aseptic inflammatory diseases. Another member of the TREM family, The Triggering receptor expressed on myeloid cells Like Transcript-1 (TLT-1) is exclusively expressed in platelets and promotes platelet aggregation. As the gene that encodes for TLT-1 is located in the TREM-1 gene cluster, this prompted us to investigate the expression of TREM-1 on platelets. Here we show that TREM-1 is constitutively expressed in α-granules and mobilised at the membrane upon platelet activation. Pharmacologic inhibition of TREM-1 reduces platelet activation as well as platelet aggregation induced by collagen, ADP, and thrombin in human platelets. Aggregation is similarly impaired in platelets from Trem-1^−/− mice. In vivo, TREM-1 inhibition decreases thrombus formation in a carotid artery model of thrombosis and protects mice during pulmonary embolism without excessive bleeding. These findings suggest that TREM-1 inhibition could be useful adducts in antiplatelet therapies.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Platelets - TREM-1

• References

• 1 American College of Emergency Physicians. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-140.
• 2 Members, 2012 Writing Committee. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2012; 126: 875-910.
• 3 Franchi F, Angiolillo D. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12: 30-47.
• 4 Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
• 5 van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85: 195-204.
• 6 Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92: 7450-7454.
• 7 Frenette PS, Denis CV, Weiss L. et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. Exp Med 2000; 191: 1413-1422.
• 8 Weber AA, Köppen HO, Schrör K. Platelet-Derived Microparticles Stimulate Coronary Artery Smooth Muscle Cell Mitogenesis by a PDGF-Independent Mechanism. Thromb Res 2000; 98: 461-466.
• 9 Projahn D, Koenen RR. Platelets: key players in vascular inflammation. Leukoc Biol 2012; 92: 1167-1175.
• 10 Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. Immunol 2000; 164: 4991-4995.
• 11 Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410: 1103-1107.
• 12 Tessarz AS, Cerwenka A. The TREM-1/DAP12 pathway. Immunol Lett 2008; 116: 111-116.
• 13 Arts RJW, Joosten LAB, van der Meer JWM, Netea MG. TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors. Leukoc Biol 2013; 93: 209-215.
• 14 Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. Immunol 2004; 172: 4956-4963.
• 15 Haselmayer P, Grosse-Hovest L, Landenberg P. et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029-1035.
• 16 Gibot S, Kolopp-Sarda MN, Béné MC. et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. Exp Med 2004; 200: 1419-1426.
• 17 Gibot S, Alauzet C, Massin F. et al. Modulation of the triggering receptor expressed on myeloid cells-1 pathway during pneumonia in rats. Infect Dis 2006; 194: 975-983.
• 18 Weber B, Schuster S, Zysset D. et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog 2014; 10: e1003900.
• 19 Derive M, Boufenzer A, Gibot S. Attenuation of responses to endotoxin by the triggering receptor expressed on myeloid cells-1 inhibitor LR12 in nonhuman primate. Anesthesiology 2014; 120: 935-942.
• 20 Liu T, Zhou Y, Li P. et al. Blocking triggering receptor expressed on myloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation. Sci Rep 2016; 06: 39473
• 21 Boufenzer A, Lemarié J, Simon T. et al. TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circ Res 2015; 116: 1772-1782.
• 22 Lemarié J, Boufenzer A, Popovic B. et al. Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Fail 2015; 02: 90-99.
• 23 Zysset D, Weber B, Rihs S. et al. TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis. Nat Commun 2016; 07: 13151
• 24 Joffre J, Potteaux S, Zeboudj L. et al. Genetic and pharmacological inhibition of TREM-1 limits the development of experimental atherosclerosis. Am Coll Cardiol 2016; 68: 2776-2793.
• 25 Allcock RJN, Barrow AD, Forbes S. et al. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur Immunol 2003; 33: 567-577.
• 26 Washington AV, Gibot S, Acevedo I. et al. A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood 2004; 104: 1042-1047.
• 27 Washington AV. et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. Clin Invest 2009; 119: 1489-1501.
• 28 Barrow AD, Astoul E, Floto A. et al. Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. Immunol 2004; 172: 5838-5842.
• 29 Giomarelli B, Washington VA, Chisholm MM. et al. Inhibition of thrombin-induced platelet aggregation using human single-chain Fv antibodies specific for TREM-like transcript-1. Thromb Haemost 2007; 97: 955-963.
• 30 Ragab A, Séverin S, Gratacap MP. et al. Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: insights into the mechanism of PLCγ2 activation. Blood 2007; 110: 2466-2474.
• 31 Furie B, Furie BC, Flaumenhaft R. A journey with platelet P-selectin: the molecular basis of granule secretion, signalling and cell adhesion. Thromb Haemost 2001; 86: 214-221.
• 32 Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179.
• 33 von Brühl ML, Stark K, Stenhart A. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. Exp Med 2012; 209: 819-835.
• 34 Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost 2015; 114: 449-458.
• 35 Toner P, McAuley DF, Shyamsundar M. Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome. Crit Care 2015; 19: 274